Using genetic tests to predict immunotherapy response in lung cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
- You have a tumor sample (from surgery or biopsy) that was taken before you started any cancer treatment like chemotherapy or radiation.
- You are in fairly good health, able to perform daily activities with some help if needed (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within normal ranges.
- You have not received prior systemic therapy (chemo or targeted pills) for your metastatic lung cancer.
- You have agreed to have your medical data and tumor sample used for research and have signed a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This study looks at how tumors respond to chemotherapy plus immunotherapy before surgery for non-small cell lung cancer. It uses genetic tests on the tumor and blood to personalize treatment and possibly improve outcomes.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.